MedTrace Logo

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

NCT05137860 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2022-01-18

No results posted yet for this study

Summary

Various drugs have been added to different treatment regimens in order to improve the response rate in patients with Acute Lymphoblastic Leukemia, however, it has been shown that adding Bortezomib to the relapsing regimen improves the proportion of second complete remissions without increasing chemotherapy toxicity. Therefore, proteasome inhibitors can drastically modify the prognosis of patients, since their synergy with drugs such as steroids has positioned them as an attractive strategy.

Conditions

  • Acute Lymphoblastic Leukemia, in Relapse
  • Chemotherapeutic Toxicity
  • Minimal Residual Disease

Interventions

DRUG

Bortezomib

Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.

Sponsors & Collaborators

  • Hospital General de Mexico

    lead OTHER_GOV

Principal Investigators

  • Adolfo Martinez Tovar, PhD · Hospital General de Mexico

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-12
Primary Completion
2022-12-22
Completion
2023-06-23

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05137860 on ClinicalTrials.gov